Quick Answer
Silence Therapeutics plc reported Earnings Per Share Diluted of $0.63 (loss) per share for the year ending 2025.
- Silence Therapeutics plc showed a decrease of -90.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Silence Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $0.02 (loss) per share | Q2 2024: $0.14 (loss) per share | Q3 2024: $0.25 (loss) per share | Q1 2025: $0.20 (loss) per share | Q2 2025: $0.19 (loss) per share | Q3 2025: $0.15 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Silence Therapeutics plc's Earnings Per Share Diluted has declined by 21.2%.
- Historical annual values: Fiscal year 2025: $0.63 (loss) per share | Fiscal year 2024: $0.33 (loss) per share | Fiscal year 2023: $0.49 (loss) per share | Fiscal year 2022: $0.52 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: